MMIRF
Price
$0.05
Change
+$0.04 (+400.00%)
Updated
Jul 22 closing price
Capitalization
38.69M
NWPHF
Price
$9.36
Change
-$2.64 (-22.00%)
Updated
Sep 9 closing price
Capitalization
177.35M
Interact to see
Advertisement

MMIRF vs NWPHF

Header iconMMIRF vs NWPHF Comparison
Open Charts MMIRF vs NWPHFBanner chart's image
Medmira
Price$0.05
Change+$0.04 (+400.00%)
Volume$1.5K
Capitalization38.69M
Newron Pharmaceuticals SPA
Price$9.36
Change-$2.64 (-22.00%)
Volume$500
Capitalization177.35M
MMIRF vs NWPHF Comparison Chart in %
Loading...
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MMIRF vs. NWPHF commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MMIRF is a Buy and NWPHF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (MMIRF: $0.05 vs. NWPHF: $9.36)
Brand notoriety: MMIRF and NWPHF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MMIRF: 18% vs. NWPHF: 100%
Market capitalization -- MMIRF: $38.69M vs. NWPHF: $177.35M
MMIRF [@Biotechnology] is valued at $38.69M. NWPHF’s [@Biotechnology] market capitalization is $177.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MMIRF’s FA Score shows that 1 FA rating(s) are green whileNWPHF’s FA Score has 1 green FA rating(s).

  • MMIRF’s FA Score: 1 green, 4 red.
  • NWPHF’s FA Score: 1 green, 4 red.
According to our system of comparison, MMIRF is a better buy in the long-term than NWPHF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MMIRF’s TA Score shows that 3 TA indicator(s) are bullish.

  • MMIRF’s TA Score: 3 bullish, 4 bearish.

Price Growth

MMIRF (@Biotechnology) experienced а +257.86% price change this week, while NWPHF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

MMIRF is expected to report earnings on Jul 01, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NWPHF($177M) has a higher market cap than MMIRF($38.7M). MMIRF YTD gains are higher at: 282.443 vs. NWPHF (0.000).
MMIRFNWPHFMMIRF / NWPHF
Capitalization38.7M177M22%
EBITDA-3.24MN/A-
Gain YTD282.4430.000-
P/E RatioN/AN/A-
Revenue254KN/A-
Total Cash18.3KN/A-
Total Debt10.2MN/A-
FUNDAMENTALS RATINGS
MMIRF vs NWPHF: Fundamental Ratings
MMIRF
NWPHF
OUTLOOK RATING
1..100
4642
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
65
Fair valued
PROFIT vs RISK RATING
1..100
10010
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3676
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a42

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MMIRF's Valuation (5) in the null industry is somewhat better than the same rating for NWPHF (65). This means that MMIRF’s stock grew somewhat faster than NWPHF’s over the last 12 months.

NWPHF's Profit vs Risk Rating (10) in the null industry is significantly better than the same rating for MMIRF (100). This means that NWPHF’s stock grew significantly faster than MMIRF’s over the last 12 months.

NWPHF's SMR Rating (100) in the null industry is in the same range as MMIRF (100). This means that NWPHF’s stock grew similarly to MMIRF’s over the last 12 months.

MMIRF's Price Growth Rating (36) in the null industry is somewhat better than the same rating for NWPHF (76). This means that MMIRF’s stock grew somewhat faster than NWPHF’s over the last 12 months.

MMIRF's P/E Growth Rating (100) in the null industry is in the same range as NWPHF (100). This means that MMIRF’s stock grew similarly to NWPHF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MMIRFNWPHF
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
N/A
Momentum
ODDS (%)
Bullish Trend 1 day ago
64%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
52%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
57%
Bullish Trend 1 day ago
13%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
67%
Bullish Trend 1 day ago
10%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TOSCF15.11N/A
N/A
Tosoh Corp.
CATWF0.07N/A
N/A
China Tontine Wines Group Ltd.
NZERF0.16N/A
N/A
New Zealand Energy Corp.
PLRRF6.40N/A
N/A
Polar Capital Holdings PLC
DLICY15.94-0.13
-0.81%
Dai-ichi Life Holdings Inc

MMIRF and

Correlation & Price change

A.I.dvisor tells us that MMIRF and NWPHF have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MMIRF and NWPHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MMIRF
1D Price
Change %
MMIRF100%
N/A
NWPHF - MMIRF
30%
Poorly correlated
N/A
TECX - MMIRF
29%
Poorly correlated
+0.18%
AZTR - MMIRF
24%
Poorly correlated
-4.34%
SRPT - MMIRF
22%
Poorly correlated
-7.38%
SAGE - MMIRF
22%
Poorly correlated
+0.46%
More

NWPHF and

Correlation & Price change

A.I.dvisor tells us that NWPHF and MMIRF have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NWPHF and MMIRF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NWPHF
1D Price
Change %
NWPHF100%
N/A
MMIRF - NWPHF
30%
Poorly correlated
N/A
ACET - NWPHF
27%
Poorly correlated
-0.54%
NTRB - NWPHF
19%
Poorly correlated
-3.18%
NURPF - NWPHF
7%
Poorly correlated
N/A
PRVCF - NWPHF
4%
Poorly correlated
N/A
More